Immuneering Corporation

NASDAQ (USD): Immuneering Corporation (IMRX)

Last Price

2.00

Today's Change

+0.16 (8.69%)

Day's Change

1.79 - 2.08

Trading Volume

678,201

Overview

Market Cap

62 Million

Shares Outstanding

31 Million

Avg Volume

1,246,388

Avg Price (50 Days)

2.01

Avg Price (200 Days)

1.87

PE Ratio

-1.02

EPS

-1.97

Earnings Announcement

05-Mar-2025

Previous Close

1.84

Open

1.79

Day's Range

1.79 - 2.08

Year Range

1.0 - 7.92

Trading Volume

678,679

Price Change Highlight

1 Day Change

8.70%

5 Day Change

22.70%

1 Month Change

-5.21%

3 Month Change

-37.69%

6 Month Change

39.86%

Ytd Change

-72.68%

1 Year Change

-71.35%

3 Year Change

-91.11%

5 Year Change

-88.63%

10 Year Change

-88.63%

Max Change

-88.63%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment